Comprehensive review highlights the link between inflammation and recurrent pregnancy loss, suggesting potential drug therapies targeting NLRP3 inflammasome.
Key Points
Recurrent pregnancy loss is linked to the activation of the nlrp3 inflammasome, suggesting a key role of inflammation.
Current therapies for recurrent pregnancy loss are limited, particularly those targeting the nlrp3 inflammasome.
Understanding the complex interactions involving nlrp3 may open avenues for novel therapeutic strategies.
Potential drug therapies targeting nlrp3 inflammasome could alleviate the burdens of recurrent pregnancy loss on affected couples.